Neutralization of interleukin-17A delays progression of silica-induced lung inflammation and fibrosis in C57BL/6 mice

Toxicol Appl Pharmacol. 2014 Feb 15;275(1):62-72. doi: 10.1016/j.taap.2013.11.012. Epub 2013 Nov 26.

Abstract

Silica exposure can cause lung inflammation and fibrosis, known as silicosis. Interleukin-17A (IL-17A) and Th17 cells play a pivotal role in controlling inflammatory diseases. However, the roles of IL-17A and Th17 cells in the progress of silica-induced inflammation and fibrosis are poorly understood. This study explored the effects of IL-17A on silica-induced inflammation and fibrosis. We used an anti-mouse IL-17A antibody to establish an IL-17A-neutralized mice model, and mice were exposed to silica to establish an experimental silicosis model. We showed that IL-17A neutralization delayed neutrophil accumulation and progression of silica-induced lung inflammation and fibrosis. IL-17A neutralization reduced the percentage of Th17 in CD4+ T cells, decreased IL-6 and IL-1β expression, and increased Tregs at an early phase of silica-induced inflammation. Neutralization of IL-17A delayed silica-induced Th1/Th2 immune and autoimmune responses. These results suggest that IL-17A neutralization alleviates early stage silica-induced lung inflammation and delays progression of silica-induced lung inflammation and fibrosis. Neutralization of IL-17A suppressed Th17 cell development by decreasing IL-6 and/or IL-1β and increased Tregs at an early phase of silica-induced inflammation. Neutralization of IL-17A also delayed the Th1/Th2 immune response during silica-induced lung inflammation and fibrosis. IL-17A may play a pivotal role in the early phase of silica-induced inflammation and may mediate the Th immune response to influence silica-induced lung inflammation and fibrosis in mice.

Keywords: IL-17A; Lung Inflammation; Lung fibrosis; Silica; Th17.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Neutralizing / therapeutic use*
  • Disease Models, Animal*
  • Disease Progression
  • Down-Regulation / drug effects
  • Female
  • Interleukin-17 / antagonists & inhibitors*
  • Interleukin-17 / metabolism
  • Interleukin-1beta / antagonists & inhibitors
  • Interleukin-1beta / genetics
  • Interleukin-1beta / metabolism
  • Interleukin-6 / antagonists & inhibitors
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism
  • Lung / drug effects*
  • Lung / immunology
  • Lung / metabolism
  • Lung / pathology
  • Mice
  • Mice, Inbred C57BL
  • Neutrophil Infiltration / drug effects
  • Pneumonia / etiology
  • Pneumonia / prevention & control*
  • Pulmonary Fibrosis / etiology
  • Pulmonary Fibrosis / prevention & control*
  • Random Allocation
  • Silicosis / drug therapy*
  • Silicosis / immunology
  • Silicosis / pathology
  • Silicosis / physiopathology
  • Specific Pathogen-Free Organisms
  • T-Lymphocytes, Helper-Inducer / drug effects
  • T-Lymphocytes, Helper-Inducer / immunology
  • T-Lymphocytes, Helper-Inducer / metabolism
  • T-Lymphocytes, Helper-Inducer / pathology
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / immunology
  • T-Lymphocytes, Regulatory / metabolism
  • T-Lymphocytes, Regulatory / pathology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Neutralizing
  • IL1B protein, mouse
  • Il17a protein, mouse
  • Interleukin-17
  • Interleukin-1beta
  • Interleukin-6
  • interleukin-6, mouse